正大企业国际2023中期报告

Incorporated in Bermuda with members’ limited liability•Stock Code : 3839於 百 慕 達 註 冊 成 立 之 成 員 有 限 責 任 公 司•股 份 代 號：3839 Contents目錄 2Management Discussion and Analysis管理層討論及分析 6Report on Review of Interim Financial Report中期財務報告之審閱報告 8Consolidated Statement of Comprehensive Income綜合全面收益表 10Consolidated Statement of Financial Position綜合財務狀況表 12Consolidated Statement of Changes in Equity綜合權益變動表 14Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表 15Notes to Interim Financial Report中期財務報告附註 31Other Information其他資料 35Corporate Information公司資料 MANAGEMENT DISCUSSION AND ANALYSIS GROUP RESULTS 本 集 團 從 事 生 化 業 務 及 工 業 業 務。生 化 業 務 專 注 於 金霉素及其他相關產品，並由本集團之附屬公司營運，乃佔本集團的所有綜合收入。工業業務包含本集團於ECIMetro Investment Co., Ltd.（及其附屬公司，統稱「ECIMetro」）的合營企業權益及於湛江德利車輛部件有限公司（及其附屬公司，統稱「湛江德利」）的聯營公司權益。本集團工業業務的業績載列於綜合全面收益表內的應佔合營企業及聯營公司溢利及虧損。 The Group has two lines of business: biochemical businessand industrial business. The biochemical business focuses onchlortetracycline (“CTC”) and other related products, and iscarried on by Group subsidiaries. This business segment accountsfor all of the Group’s consolidated revenue. The industrialbusiness comprises the Group’s interests in its joint ventureECI Metro Investment Co., Ltd. (together with its subsidiaries,“ECI Metro”) and its associate Zhanjiang Deni Vehicle PartsCo., Ltd. (together with its subsidiaries, “Zhanjiang Deni”). Theresults of the Group’s industrial business are incorporated in theconsolidated statement of comprehensive income as share ofprofits and losses of joint venture and associate. 截至二零二三年六月三十日止六個月（「二零二三年上半年」），本集團的收入上升2.0%至8,281萬美元。截至二零二二年六月三十日止六個月（「二零二二年上半年」），本集團的收入為8,121萬美元。整 體毛 利率為22.3%（二零二二年上半年：23.6%）。 For the six months ended 30 June 2023 (“1H23”), the Group’srevenue increased by 2.0% to US$82.81 million. For the sixmonths ended 30 June 2022 (“1H22”), the Group’s revenue wasUS$81.21 million. Overall gross profit margin was at 22.3%(1H22: 23.6%). 本公司股東應佔溢利為203萬美元（二零二二年上半年：虧損498萬美元）。由虧轉盈主要由於工業業務表現有改善，應佔ECI Metro溢利及虧損從二零二二年上半年虧損534萬美元改善至二零二三年上半年盈利261萬美元。 Profit attributable to shareholders of the Company was US$2.03million (1H22: loss of US$4.98 million). The turn from loss toprofit was mainly due to improved performance of our industrialbusiness. Share of profits and losses of ECI Metro improved from aloss of US$5.34 million in 1H22 to a profit of US$2.61 million in1H23. 每股基本及攤薄溢利為0.80美仙（二零二二年上半年：虧損1.97美仙）。本公司董事會決議截至二零二三年六月三十日止六個月不派付中期股息（二零二二年上半年：無）。 Basic and diluted profit per share were both 0.80 US cents(1H2022: loss of 1.97 US cents). The board of directors of theCompany resolved not to declare an interim dividend for the sixmonths ended 30 June 2023 (1H22: Nil). BUSINESS REVIEW Biochemical 我們的收入大部分來自製造及銷售金霉素產品（金霉素預混劑及鹽酸金霉素）和動保化藥產品。金霉素產品為用作預防或治療動物疾病的抗生素。而我們的動保化藥產品主要是用作家畜疾病的防治藥。近年，我們一直在戰略性地擴大我們的產品組合，以涵蓋其他相關的獸藥產品。在這些新產品中，一部分我們製造及銷售，一部分我們採購和貿易。本集團的主要客戶包括養殖場、製藥公司、貿易公司及飼料加工廠。 Wegenerate a sizable portion of our revenue from themanufacture and sale of CTC products (CTC Premix and CTCHCL) and animal health products. CTC products are antibioticsused to prevent or cure animal diseases. While our animal healthproducts are mainly preventive drugs for livestock diseases. Inthe past few years, we have been strategically broadening ourproduct portfolio to cover other related veterinary products. Ofthese new offerings, some we manufacture and sale, and some wesource and trade. The Group’s major customers include farms,pharmaceutical companies, trading companies and feed mills. 二 零 二 三 年 上 半 年，本 集 團 生 化 業 務 的 收 入 為8,281萬美元（二零二二年上半年：8,121萬美元）。在銷售保持穩定的同時，我們的銷售結構隨著我們的戰略業務方向發生了變化。金霉素產品的收入佔比從二零二二年上半年的57%下降至二零二三年上半年的48%，而動保化藥產品、貿易和其他部分的收入佔比從二零二二年上半年的43%增加至二零二三年上半年的52%。二零二三年上半年的毛利率為22.3%（二零二二年上半年：23.6%）。 In 1H23, the Group’s revenue from the biochemical businessamounted to US$82.81 million (1H22: US$81.21 million). Whilesales remained stable, our sales mix changed in line with ourstrategic business direction. Revenue contribution from CTCproducts decreased from 57% in 1H22 to 48% in 1H23, whilerevenue contribution from animal health products, trading andother segments increased from 43% in 1H22 to 52% in 1H23.Gross profit margin in 1H23 was 22.3% (1H22: 23.6%). 由於金霉素產品的需求於二零二三年上半年減少，我們的工廠使用率下降，增加了我們在此期間的生產間接成本。再者，隨著我們的戰略業務方向，我們繼續部署額外的營銷工作以擴大我們的動保化藥和貿易業務。總體而言，我們的生化業務貢獻在二零二三年上半年有所下降。 Due to reduced CTC product demand in 1H23, our factoryutilisation rate dropped, increasing our production overhead inthis period. Again, in line with our strategic business direction,we continued to deploy additional marketing efforts to expandour animal health and trading businesses. Overall, contributionfrom our biochemical business declined in 1H23. Industrial 本集團的工業業務透過ECI Metro及湛江德利經營。 The Group’s industrial business is conducted through ECI Metroand Zhanjiang Deni. ECI Metro主要在中國西部從事卡特彼勒機械設備的銷售、租賃及維修服務。自二零二二年，中國挖掘機市場受工程機械需求下滑。據中國工程機械工業協會統計，二零二三年上半年挖掘機總體巿場銷量比二零二二上半年下降43.8%。中小型工程機械的市場份額也不斷受到國內品牌生產商的挑戰。然而，銷售零件及維修服務的收入和毛利因需求上升而增加。此外，符合新排放標準的機械有較好毛利率。因此，截至二零二三年六月三十日止六個月，應佔合營